Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
175 hedge funds and large institutions have $899M invested in Acorda Therapeutics in 2016 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 59 increasing their positions, 57 reducing their positions, and 18 closing their positions.
56% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 18
5% more funds holding
Funds holding: 167 → 175 (+8)
4% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 57
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less capital invested
Capital invested by funds: $1.01B → $899M (-$108M)
83% less call options, than puts
Call options by funds: $7.01M | Put options by funds: $40.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$14.3M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$12.4M |
| 3 |
SCM
Scopia Capital Management
New York
|
+$6.5M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$5.23M |
| 5 |
Millennium Management
New York
|
+$4.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$13.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$10.8M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.44M |
| 4 |
Goldman Sachs
New York
|
-$7.54M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$7.43M |
ACOR Hedge Fund Activity: Q4 2016 in Review
175 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q4 2016, worth a combined $899M — down 11% from $1.01B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ACOR positions and 18 closed out — a net gain of 10 holders — while 59 added to existing stakes and 57 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $14.3M. The largest seller was Eagle Asset Management, cutting an estimated $13.7M.
- 175 institutional investors held Acorda Therapeutics (ACOR) as of Q4 2016, up from 167 in Q3 2016.
- Funds reported $899M of Acorda Therapeutics stock for Q4 2016, down 11% quarter-over-quarter.
- 28 funds opened new Acorda Therapeutics positions in Q4 2016 and 18 closed out, a net change of +10 holders.
- The largest Acorda Therapeutics buyer in Q4 2016 was Perceptive Advisors, an estimated $14.3M added.
- The largest Acorda Therapeutics seller in Q4 2016 was Eagle Asset Management, an estimated $13.7M sold.
Based on aggregated 13F filings for Q4 2016.